Skip to content
PeptideAI
Human trialslongevitysleepimmunehormone support

Epithalamin

The original bovine pineal peptide extract behind the whole Khavinson programme, injected in ten-day courses for circadian and neuroendocrine normalisation, and the compound used in the only long-term human mortality study the category has.

Also known as Epithalamine, pineal peptide extract, epiphysis peptide complex, Cytomax pineal, Epitalon precursor, Epithalamin, Endoluten

Human trials — Studied in people, typically early phase or small — promising rather than proven.

This is the only bioregulator with genuine long-term human outcome data: Khavinson and Morozov's 2003 report followed 266 people over 60 for six to eight years and described a 1.6-1.8-fold mortality reduction with Epithalamin alone, and up to a 4.1-fold reduction with Thymalin plus repeated annual courses. That is a striking result that has never been replicated by anyone outside the group that produced it, was published in a low-impact journal, and would not survive a modern trial registry. Treat it as promising and unconfirmed, not as settled.

How it works

Epithalamin is not a single molecule; it is an acid-extracted peptide fraction from the pineal glands of calves under twelve months old, with components below roughly 5 kDa. Russian work attributes its effects to restoration of nocturnal melatonin output, resensitisation of the hypothalamic-pituitary axis to feedback, and antioxidant activity. The synthetic tetrapeptide Epitalon (Ala-Glu-Asp-Gly) was isolated as the putative active core, and the telomerase-activation claims made for Epitalon are frequently and loosely transferred back onto the extract. Because the material is a mixture whose exact composition is not published lot by lot, no receptor-level mechanism has ever been pinned down.

Targets: Pineal gland, Melatonin synthesis, Hypothalamic-pituitary axis

Dosing

ProtocolDoseFrequencyRoute
Classic Russian courseGiven in the evening by most users because of the melatonin framing, though the original protocols did not specify time of day.10 mgonce daily for 5 to 10 consecutive daysintramuscular
Subcutaneous substitutionEvening.5 mg – 10 mgonce daily for 10 dayssubcutaneous
  • · 10 mg per day for 5-10 days is the dose used across the Khavinson clinical literature, repeated once or twice a year.
  • · Most Western users inject subcutaneously rather than intramuscularly. There is no comparative bioavailability data between the two routes for this material.

Cycling

Ten-day courses, one to two courses per year. The mortality-cohort protocol that everyone cites gave courses annually for six years - continuous daily use is not how this compound was ever studied.

Work out your exact syringe units →

Pharmacology

Half-life
Never measured; the peptide fraction is presumed to clear from plasma within minutes, with any effect outlasting the exposure.
Onset
Sleep and circadian changes are usually reported within the first week of a course; the claimed systemic effects are framed as building over repeated annual courses.
Routes
intramuscular, subcutaneous
Molecule
Bovine pineal-derived low-molecular-weight peptide complex

Handling

Diluent
Bacteriostatic water or sterile saline
Typical mix
1 or 2 mL
Vial sizes
10 mg
Lyophilised
Refrigerate at 2-8 C; the manufacturer's own labelling specifies cold storage rather than the room-temperature tolerance typical of synthetic peptides.
Reconstituted
Refrigerated and used within about 7-10 days - this is a biological extract, not a pure synthetic, so give it less benefit of the doubt.
Light sensitive
Yes — keep it out of the light

Mixing

A 10 mg vial in 1 mL gives 10 mg/mL, so one full 100-unit insulin syringe is a whole day's dose. Aim the stream at the vial wall and swirl.

Side effects

  • commonInjection-site soreness— More pronounced intramuscularly than subcutaneously.
  • commonDaytime drowsiness or vivid dreams— Consistent with the melatonin-rhythm shift the compound is meant to produce.
  • uncommonHeadache in the first few days— Usually settles without stopping the course.
  • rareAllergic reaction to bovine protein— This is animal-tissue-derived material; true hypersensitivity is possible in a way it is not with synthetic peptides.

Do not use if

  • Known allergy to bovine protein - this is a calf-tissue extract, not a synthetic molecule.
  • Pregnancy and breastfeeding - no safety data of any kind exists.
  • Active malignancy - the telomerase-activation claims attached to this family are unresolved and cut the wrong way here.
  • Do not use product of unverified origin: animal-tissue extracts carry a theoretical transmissible spongiform encephalopathy risk that a synthetic peptide does not.

Combining it

  • redundantepitalon — Epitalon is the synthetic tetrapeptide isolated from this extract; running both is duplication, not stacking.
  • synergythymalin-cytomax — The combination is the one that produced the largest mortality reduction in Khavinson's cohort - this pairing is the entire basis of the category's reputation.
  • cautionmelatonin — Both push the same circadian lever; stacking them tends to produce grogginess rather than better sleep.

What to monitor

  • · Track sleep onset, wake time and subjective sleep quality - this is the effect that shows up soonest and most reliably.
  • · No routine bloodwork is established for this compound.

Legal status

Not approved as a drug in the US, UK or EU. Registered and manufactured in Russia; sold in the West as a research chemical or, in capsule form, as a food supplement.

References

  • Khavinson & Morozov 2003, peptides of pineal gland and thymus prolong human life (Neuroendocrinology Letters) (trial)
  • Anisimov & Khavinson, peptide bioregulation of aging: results and prospects (Biogerontology) (review)
  • Khavinson, Peptides and Ageing (Neuroendocrinology Letters supplement monograph) (review)

Mechanism in depth

The honest mechanistic picture is that nobody knows, and the parts that are known point somewhere other than where the marketing does. What has actually been measured in humans is melatonin. Korkushko's group gave epithalamin to elderly subjects and reported that it modulated rather than simply raised nocturnal pineal output: people who started with low nighttime melatonin went up, people who started normal went down. That is an adaptive, thermostat-like description rather than a dose-response one, and it is the single most reproducible human observation attached to the compound. The same group reported the same normalising pattern in aged rhesus monkeys. If you believe anything about Epithalamin, believe that it does something to circadian melatonin amplitude in people whose amplitude has already flattened, and expect nothing if yours has not. The second strand is oncological rather than endocrine. Anisimov ran epithalamin through Drosophila, mice and rats across two decades and reported lifespan extension alongside reduced spontaneous tumour incidence, which he framed through the pineal-melatonin-oestrogen axis rather than through anything epigenetic. The chromatin and telomerase story that dominates the modern marketing belongs to Epitalon, the synthetic tetrapeptide, not to the extract, and transferring it backwards is the most common error made about this compound. There is no receptor. There is no binding assay. There is no dose-response curve in a human being.

What usually goes wrong

The commonest failure is attribution. People run a ten-day Epithalamin course inside a stack of four other compounds, sleep better, and credit the pineal extract. The second failure is believing the mortality numbers transfer to you. That cohort was people over 60 with existing age-related pathology, dosed annually for years; a 35-year-old running one course a year is not in that population and has no basis for expecting anything. The third is source. This is calf tissue, not a synthetic molecule, and the supply chain runs through grey-market resellers of a Russian pharmaceutical. Unverified animal-tissue extract carries a real, if small, transmissible spongiform encephalopathy question that a synthetic tetrapeptide simply does not, and no amount of vendor certificate-of-analysis paperwork addresses it because a COA on a polydisperse extract cannot say much. Fourth, people escalate. There is no dose above 10 mg per day in the literature; running 20 mg because it is a longevity compound and more must be better is invention.

Bloodwork worth running

MarkerWhenWhy it matters
Overnight urinary 6-sulphatoxymelatonin, or a salivary melatonin curveA baseline collection over one night before the course, then repeat two to four weeks after the last injection.This is the one endpoint with actual human data behind it. If Epithalamin does anything to you, this is where it shows up. Serum melatonin from a single daytime draw is useless - the whole claim is about nighttime amplitude.Act if: The published pattern is bidirectional: low baseline goes up, normal baseline goes down. If your baseline amplitude is already normal, that is a reason to skip the compound rather than a reason to dose higher.
IGF-1Baseline and at the end of any multi-compound protocol.Not because Epithalamin is claimed to move it, but because the longevity crowd running this compound is usually running several others, and IGF-1 is the marker that quietly reveals a GH secretagogue in the stack that you have attributed to the peptide extract.Act if: Any movement in IGF-1 during an Epithalamin course is coming from something else in your stack. Go find it.
CBC with differentialBaseline and two to four weeks post-course, especially on a first exposure.Cheap, and it is the only routine panel that would catch an unexpected reaction to a bovine tissue extract - eosinophilia in particular.Act if: New eosinophilia above about 0.5 x10^9/L after a course of an animal-derived extract is a sensitisation signal. Stop and do not repeat the course.

Pharmacokinetics

Metabolism
Proteolysis to constituent amino acids by plasma and tissue peptidases. No metabolite has ever been identified, and no cytochrome P450 involvement is plausible for a peptide of this size.
Elimination
Renal filtration of fragments and recycling of amino acids into the general pool. Nothing has been measured.

Receptor targets

  • No identified cell-surface or nuclear receptor — None published for any component of the fraction

    Nothing in fifty years of work on this material has produced a receptor, a Kd, or a saturable binding site. Any vendor claiming a receptor mechanism has invented it.

  • Pineal melatonin output (functional target, not a molecular one)

    Bidirectional normalisation of nocturnal melatonin amplitude in elderly subjects and aged primates - raised when low, lowered when already normal. This is the best-supported functional endpoint the compound has.

  • Thymus-pineal circadian coupling

    Labunets reported that epithalamin altered the circadian relationship between thymic hormone output and pineal function in elderly people, which is the mechanistic bridge Khavinson uses to justify pairing it with Thymalin.

Trials

  • Khavinson & Morozov geroprotection cohort, St Petersburg Not a registered trial - open, controlled long-term cohort predating trial registration · n=266 · 2003

    All-cause mortality over six to eight years of follow-up in people over 60, with the bioregulators given during only the first two to three years. Epithalamin alone was reported to reduce mortality 1.6-1.8-fold; Thymalin plus Epithalamin with repeated annual courses was reported at 4.1-fold. Incidence of respiratory disease fell 2.0-2.4-fold. No registration, no blinding described, no independent monitoring, no replication by anyone outside the originating institute.

  • Korkushko 12-year randomised study of epithalamine in elderly coronary patients (Institute of Gerontology, Kiev) Described as a randomised clinical study; not registered, blinding not described · 624 weeks · 2006

    Twelve-year mortality in elderly patients with coronary disease and accelerated cardiovascular ageing. Reported 28 percent lower all-cause mortality, roughly halved cardiovascular mortality, and a halving of cardiac failure and respiratory disease incidence versus controls on the same background therapy. Participant count is not stated in the published abstract.

  • Korkushko melatonin-rhythm study in elderly subjects Open clinical study · 2004

    Circadian melatonin-producing function of the pineal gland in elderly people. Epithalamin modulated rather than uniformly raised output - nighttime melatonin increased in subjects with low baseline pineal activity and decreased in those with normal function.

  • Korkushko & Lapin pineal peptide study in aged rhesus monkeys and senior citizens Preclinical primate plus open human observation · 2007

    Normalisation of the melatonin rhythm in aged monkeys and elderly humans. The primate arm is the closest thing this compound has to a controlled non-human-primate result.

What to expect, and when

Days one to three: nothing reliable. Some people report vivid dreams or a heavier sleep onset from the first or second evening injection, which is consistent with a melatonin-amplitude shift but is also exactly what expectation produces. Days three to ten: if sleep is going to change, this is when. Track sleep onset latency, not how you feel about your sleep. Weeks two to six after the course ends: the melatonin normalisation reported by Korkushko was measured after the course, not during it, so this is the window where a urinary 6-sulphatoxymelatonin retest is meaningful. Months to years: everything else claimed for this compound - mortality, cardiovascular ageing, tumour incidence - is framed over repeated annual courses across years, and there is no way for an individual to observe it.

Stacking and comparisons

The only stack with any data behind it is Epithalamin plus Thymalin, and that pairing is not a bodybuilding-forum invention - it is the arm of the 266-person cohort that reported the 4.1-fold mortality difference. If you are going to run this category at all, run that combination in ten-day courses rather than assembling six Cytogens. Do not stack Epithalamin with Epitalon or Endoluten: those are the same claimed active in synthetic and oral form respectively, and running all three is one claim paid for three times. Adding exogenous melatonin defeats the stated purpose. The whole premise is restoring your own rhythm amplitude; 3 mg of melatonin at 10pm overrides that measurement completely and leaves you unable to tell what the peptide did.

Against Epitalon: Epitalon is the defined synthetic tetrapeptide, cheap, stable and reproducible, and it carries the telomerase and chromatin work. Epithalamin is the undefined extract and carries the human mortality data. You cannot have both properties in one vial, and the choice is genuinely between a known molecule with weak evidence and an unknown mixture with the strongest evidence the category has. Against Endoluten: same source material in a capsule, with an entirely unverified extra assumption - that the fraction survives digestion. The injection has the data; the capsule borrows it. Against exogenous melatonin: melatonin is cheap, has hundreds of randomised trials, and reliably shifts sleep onset. If your goal is sleep, melatonin wins on every axis. Epithalamin's distinct claim is amplitude restoration rather than replacement, and that claim rests on two small studies from one collaborating pair of institutes.

Rough cost

$80–$260/month. A ten-day course is ten 10 mg vials, which is how the Russian product is boxed. Because courses run once or twice a year rather than monthly, the real annual cost is closer to one or two course prices than to twelve monthly ones. These figures are indicative of the grey market rather than verified against vendor listings in this session - treat them as an order of magnitude, not a quote.

Genuinely uncertain

  • No pharmacokinetic parameter of any kind has been measured for this material - no tmax, no half-life, no volume of distribution, no clearance, no protein binding, by any route.
  • The composition of the extract is not published lot by lot, so batch-to-batch equivalence is assumed rather than demonstrated.
  • The 2003 mortality cohort is unreplicated by anyone outside Khavinson's institute and predates trial registration, blinding standards and independent data monitoring.
  • Participant numbers were not stated in the abstract of the 2006 Korkushko twelve-year study, so the durationWeeks figure of 624 is from the stated twelve years but the sample size is genuinely unknown to me.
  • Whether the intramuscular and subcutaneous routes are equivalent for this material has never been tested; the Russian protocols are intramuscular and Western users almost all inject subcutaneously.
  • Blood-brain barrier penetration is unknown. Given the claimed pineal action, this matters, and no one has measured it.
  • The telomerase and chromatin claims frequently attached to Epithalamin belong to Epitalon, the synthetic tetrapeptide. I could not find any telomerase work performed on the extract itself.
  • Cost figures are indicative grey-market estimates and were not verified against live vendor listings in this session.

Papers